Brief: Reviva To Present Negative Symptom Data For Brilaroxazine In Schizophrenia From Phase 3 Trials At CNS Summit 2025
28/10/2025 12:19
Oct 28 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O: REVIVA TO PRESENT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE IN SCHIZOPHRENIA FROM THE PHASE 3 RECOVER DOUBLE-BLIND AND OPEN-LABEL EXTENSION TRIALS AT THE CNS SUMMIT 2025 Source text: ID:nGNX4ZsddB Further company coverage: RVPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture